Vidupiprant, also known as AMG853, is a potent, selective orally bioavailable a dual D-prostanoid and CRTH2 inhibitor. Clinical trail results published on 2013 (J Allergy Clin Immunol. 2013 Feb;131(2):339-45) showed that AMG 853 as an add-on to inhaled corticosteroid therapy demonstrated no associated risks but was not effective at improving asthma symptoms or lung function in patients with inadequately controlled moderate-to-severe asthma.